Genetic variations associated with interindividual sensitivity in the response to arsenic exposure

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Abernathy CO, Liu YP, Longfellow D et al.: Arsenic: health effects, mechanisms of actions, and research issues. Environ. Health Perspect.107,593–597 (1999).
  Medline CASGoogle Scholar
• 2  Astolfi E, Maccagno A, Fernandez JC, Vaccara R, Stimola R: Review: relation between arsenic in drinking water and skin cancer. Biol. Trace Elem. Res.3,133–143 (1981).
  Medline CASGoogle Scholar
• 3  Taylor PR, Qiao YL, Schatzkin A et al.: Relation of arsenic exposure to lung cancer among tin miners in Yunnan Province, China. Br. J. Ind. Med.46,881–886 (1989).
  Medline CASGoogle Scholar
• 4  Chen WT, Hung WC, Kang WY, Huang YC, Chai CY: Urothelial carcinomas arising in arsenic-contaminated areas are associated with hypermethylation of the gene promoter of the death-associated protein kinase. Histopathology51,785–792 (2007).
  MedlineGoogle Scholar
• 5  Steinmaus C, Yuan Y, Bates MN, Smith AH: Case–control study of bladder cancer and drinking water arsenic in the western United States. Am. J. Epidemiol.158,1193–1201 (2003).
  MedlineGoogle Scholar
• 6  Bates MN, Rey OA, Biggs ML et al.: Case–control study of bladder cancer and exposure to arsenic in Argentina. Am. J. Epidemiol.159,381–389 (2004).
  MedlineGoogle Scholar
• 7  Chen CJ, Wang SL, Chiou JM et al.: Arsenic and diabetes and hypertension in human populations: a review. Toxicol. Appl. Pharmacol.222,298–304 (2007).
  Medline CASGoogle Scholar
• 8  Diaz-Villasenor A, Burns AL, Hiriart M, Cebrian ME, Ostrosky-Wegman P: Arsenic-induced alteration in the expression of genes related to Type 2 diabetes mellitus. Toxicol. Appl. Pharmacol.225,123–133 (2007).
  Medline CASGoogle Scholar
• 9  Tseng CH: Cardiovascular disease in arsenic-exposed subjects living in the arseniasis-hyperendemic areas in Taiwan. Atherosclerosis199(1),12–18 (2008).
  Medline CASGoogle Scholar
• 10  Guha Mazumder DN: Arsenic and liver disease. J. Indian Med. Assoc.99,311–314, 318–320 (2001).
  Medline CASGoogle Scholar
• 11  Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood111,2505–2515 (2008).
  Medline CASGoogle Scholar
• 12  Dilda PJ, Hogg PJ: Arsenical-based cancer drugs. Cancer Treat. Rev.33,542–564 (2007).
  Medline CASGoogle Scholar
• 13  Westervelt P, Brown RA, Adkins DR et al.: Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood98,266–271 (2001).
  Medline CASGoogle Scholar
• 14  Bencko V, Dobisova A, Macaj M: Arsenic in the hair of a non-occupationally exposed population. Atmos. Environ.5,275–279 (1971).
  Medline CASGoogle Scholar
• 15  Zakharyan RA, Sampayo-Reyes A, Healy SM et al.: Human monomethylarsonic acid (MMA[V]) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol.14,1051–1057 (2001).
  Medline CASGoogle Scholar
• 16  Lin S, Shi Q, Nix FB et al.: A novel S-adenosyl-L-methionine:arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem.277,10795–10803 (2002).
  Medline CASGoogle Scholar
• 17  Zakharyan RA, Ayala-Fierro F, Cullen WR, Carter DM, Aposhian HV: Enzymatic methylation of arsenic compounds. VII. Monomethylarsonous acid (MMAIII) is the substrate for MMA methyltransferase of rabbit liver and human hepatocytes. Toxicol. Appl. Pharmacol.158,9–15 (1999).
  Medline CASGoogle Scholar
• 18  Vahter M, Lind B: Concentrations of arsenic in urine of the general population in Sweden. Sci. Total Environ.54,1–12 (1986).
  Medline CASGoogle Scholar
• 19  Johnson LR, Farmer JG: Use of human metabolic studies and urinary arsenic speciation in assessing arsenic exposure. Bull. Environ. Contam. Toxicol.46,53–61 (1991).
  Medline CASGoogle Scholar
• 20  Hall M, Chen Y, Ahsan H et al.: Blood arsenic as a biomarker of arsenic exposure: results from a prospective study. Toxicology225,225–233 (2006).
  Medline CASGoogle Scholar
• 21  Rossman TG: Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res.533,37–65 (2003).•• Interesting review that tries to integrate arsenic metabolism, genotoxic and nongenotoxic mechanisms and incidence of arsenic-related cancer. In contrast to the previous lack of good animal models to explain arsenic-related mechanisms, the paper reviews some promising new models for these cancers. The importance of the metabolism of inorganic arsenic to various methylated forms is also included.
  Medline CASGoogle Scholar
• 22  Vahter M, Concha G: Role of metabolism in arsenic toxicity. Pharmacol. Toxicol.89,1–5 (2001).
  Medline CASGoogle Scholar
• 23  Hsueh YM, Ko YF, Huang YK et al.: Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicol. Lett.137,49–63 (2003).
  Medline CASGoogle Scholar
• 24  Vahter M: Methylation of inorganic arsenic in different mammalian species and population groups. Sci. Prog.82(Pt 1),69–88 (1999).
  Medline CASGoogle Scholar
• 25  Loffredo CA, Aposhian HV, Cebrian ME, Yamauchi H, Silbergeld EK: Variability in human metabolism of arsenic. Environ. Res.92,85–91 (2003).
  Medline CASGoogle Scholar
• 26  Chung JS, Kalman DA, Moore LE et al.: Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ. Health Perspect.110,729–733 (2002).
  Medline CASGoogle Scholar
• 27  Wood TC, Salavagionne OE, Mukherjee B et al.: Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J. Biol. Chem.281,7364–7373 (2006).
  Medline CASGoogle Scholar
• 28  Thomas DJ, Li J, Waters SB et al.: Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. (Maywood)232,3–13 (2007).
  Medline CASGoogle Scholar
• 29  Cullen WR, Reimer KJ: Arsenic speciation in the environment. Chem. Rev.89,713–764 (1989).•• Together with [30], is very important in the context of this review and in the field assessing for the biological effects of arsenic. They represent two important steps in the understanding of the arsenic metabolism pathways, since they proposed the two models usually used to explain how inorganic arsenic is metabolized in the body.
  CASGoogle Scholar
• 30  Hayakawa T, Kobayashi Y, Cui X, Hirano S: A new metabolic pathway of arsenite: arsenic–glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch. Toxicol.79,183–191 (2005).•• Together with [29], is very important in the context of this review and in the field assessing for the biological effects of arsenic. They represent two important steps in the understanding of the arsenic metabolism pathways, since they proposed the two models usually used to explain how inorganic arsenic is metabolized in the body.
  Medline CASGoogle Scholar
• 31  Naranmandura H, Suzuki N, Suzuki KT: Trivalent arsenicals are bound to proteins during reductive methylation. Chem. Res. Toxicol.19,1010–1018 (2006).
  Medline CASGoogle Scholar
• 32  Meza MM, Yu L, Rodriguez YY et al.: Developmentally restricted genetic determinants of human arsenic metabolism: association between urinary methylated arsenic and CYT19 polymorphisms in children. Environ. Health Perspect.113,775–781 (2005).
  Medline CASGoogle Scholar
• 33  Schläwicke Engstrom K, Broberg K, Concha G, Nermell B, Warholm M, Vahter M: Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ. Health Perspect.115,599–605 (2007).
  MedlineGoogle Scholar
• 34  Lindberg AL, Kumar R, Goessler W et al.: Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ. Health Perspect.115,1081–1086 (2007).
  Medline CASGoogle Scholar
• 35  Hernández A, Xamena N, Surralles J et al.: Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat. Res.637,80–92 (2008).
  Medline CASGoogle Scholar
• 36  Hernández A, Xamena N, Sekaran C et al.: High arsenic metabolic efficiency in AS3MT287Thr allele carriers. Pharmacogenet. Genomics18,349–355 (2008).
  Medline CASGoogle Scholar
• 37  de Chaudhuri S, Ghosh P, Sarma N et al.: Genetic variants associated with arsenic susceptibility: study of purine nucleoside phosphorylase, arsenic (+3) methyltransferase, and glutathione S-transferase Ω genes. Environ. Health Perspect.116,501–505 (2008).
  Medline CASGoogle Scholar
• 38  Fujihara J, Kunito T, Takeshita H: Frequency of two human glutathione-S-transferase omega-1 polymorphisms (E155 deletion and E208K) in Ovambo and Japanese populations using the PCR-based genotyping method. Clin. Chem. Lab. Med.45,621–624 (2007).
  Medline CASGoogle Scholar
• 39  Radabaugh TR, Sampayo-Reyes A, Zakharyan RA, Aposhian HV: Arsenate reductase II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem. Res. Toxicol.15,692–698 (2002).
  Medline CASGoogle Scholar
• 40  Gregus Z, Nemeti B: Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol. Sci.70,13–19 (2002).
  Medline CASGoogle Scholar
• 41  Yu L, Kalla K, Guthrie E, Vidrine A, Klimecki WT: Genetic variation in genes associated with arsenic metabolism: glutathione S-transferase Ω 1-1 and purine nucleoside phosphorylase polymorphisms in European and indigenous Americans. Environ. Health Perspect.111,1421–1427 (2003).
  Medline CASGoogle Scholar
• 42  Nemeti B, Csanaky I, Gregus Z: Arsenate reduction in human erythrocytes and rats – testing the role of purine nucleoside phosphorylase. Toxicol. Sci.74,22–31 (2003).
  Medline CASGoogle Scholar
• 43  Patterson TJ, Ngo M, Aronov PA, Reznikova TV, Green PG, Rice RH: Biological activity of inorganic arsenic and antimony reflects oxidation state in cultured human keratinocytes. Chem. Res. Toxicol.16,1624–1631 (2003).
  Medline CASGoogle Scholar
• 44  Nemeti B, Gregus Z: Glutathione-dependent reduction of arsenate in human erythrocytes – a process independent of purine nucleoside phosphorylase. Toxicol. Sci.82,419–428 (2004).
  Medline CASGoogle Scholar
• 45  Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG: Characterization of the human Ω class glutathione transferase genes and associated polymorphisms. Pharmacogenetics13,131–144 (2003).
  Medline CASGoogle Scholar
• 46  McCollum G, Keng PC, States JC, McCabe MJ Jr: Arsenite delays progression through each cell cycle phase and induces apoptosis following G₂/M arrest in U937 myeloid leukemia cells. J. Pharmacol. Exp. Ther.313,877–887 (2005).
  Medline CASGoogle Scholar
• 47  Marnell LL, Garcia-Vargas GG, Chowdhury UK et al.: Polymorphisms in the human monomethylarsonic acid (MMA^V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem. Res. Toxicol.16,1507–1513 (2003).
  Medline CASGoogle Scholar
• 48  Mukherjee B, Salavaggione OE, Pelleymounter LL et al.: Glutathione S-transferase Ω 1 and Ω 2 pharmacogenomics. Drug Metab. Dispos.34,1237–1246 (2006).
  Medline CASGoogle Scholar
• 49  Tanaka-Kagawa T, Jinno H, Hasegawa T et al.: Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn). Biochem. Biophys. Res. Commun.301,516–520 (2003).
  Medline CASGoogle Scholar
• 50  Schmuck EM, Board PG, Whitbread AK et al.: Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Ω class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer’s and Parkinson’s diseases. Pharmacogenet. Genomics15,493–501 (2005).
  Medline CASGoogle Scholar
• 51  Paiva L, Marcos R, Creus A, Coggan M, Oakley AJ, Board PG: Polymorphism of glutathione transferase Ω 1 in a population exposed to a high environmental arsenic burden. Pharmacogenet. Genomics18,1–10 (2008).
  Medline CASGoogle Scholar
• 52  Board PG, Coggan M, Chelvanayagam G et al.: Identification, characterization, and crystal structure of the Ω class glutathione transferases. J. Biol. Chem.275,24798–24806 (2000).
  Medline CASGoogle Scholar
• 53  Ahsan H, Chen Y, Kibriya MG et al.: Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Cancer Epidemiol. Biomarkers Prev.16,1270–1278 (2007).• Large case–control study to investigate interindividual variability in susceptibility to health effects of inorganic arsenic due to arsenic metabolism efficiency, genetic factors and their interaction. A total of 594 cases of arsenic-induced skin lesions and 1041 controls were included in the study. GSTO1 and MTHFR polymorphisms were selected. The analysis of joint effects of genotypes/diplotypes with water arsenic concentration and urinary %monomethylarsonic suggests additivity of these factors.
  Medline CASGoogle Scholar
• 54  Whitbread AK, Masoumi A, Tetlow N, Schmuck E, Coggan M, Board PG: Characterization of the Ω class of glutathione transferases. Meth. Enzymol.401,78–99 (2005).
  Medline CASGoogle Scholar
• 55  Chowdhury UK, Zakharyan RA, Avram MD et al.: Inorganic arsenic biotransformation and MMA(V) reductase/GSTO1-1 knockout mice. Presented at: 44th Annual Meeting of the Society of Toxicology, New Orleans, LA, USA, 6–10 March (2005).
  Google Scholar
• 56  Chowdhury UK, Zakharyan RA, Hernandez A, Avram MD, Kopplin MJ, Aposhian HV: Glutathione-S-transferase-omega [MMA(V) reductase] knockout mice: enzyme and arsenic species concentrations in tissues after arsenate administration. Toxicol. Appl. Pharmacol.216,446–457 (2006).
  Medline CASGoogle Scholar
• 57  Flora SJ, Bhadauria S, Kannan GM, Singh N: Arsenic induced oxidative stress and the role of antioxidant supplementation during chelation: a review. J. Environ. Biol.28,333–347 (2007).
  Medline CASGoogle Scholar
• 58  Pi J, Yamauchi H, Kumagai Y et al.: Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ. Health Perspect.110,331–336 (2002).
  Medline CASGoogle Scholar
• 59  Fujino Y, Guo X, Liu J et al.: Chronic arsenic exposure and urinary 8-hydroxy-2´-deoxyguanosine in an arsenic-affected area in Inner Mongolia, China. J. Expo. Anal. Environ. Epidemiol.15,147–152 (2005).
  Google Scholar
• 60  Wang TS, Shu YF, Liu YC, Jan KY, Huang H: Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology121,229–237 (1997).
  Medline CASGoogle Scholar
• 61  Schuliga M, Chouchane S, Snow ET: Upregulation of glutathione-related genes and enzyme activities in cultured human cells by sublethal concentrations of inorganic arsenic. Toxicol. Sci.70,183–192 (2002).
  Medline CASGoogle Scholar
• 62  Cotton SC, Sharp L, Little J, Brockton N: Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am. J. Epidemiol.151,7–32 (2000).
  Medline CASGoogle Scholar
• 63  Strange RC, Lear JT, Fryer AA: Polymorphism in glutathione S-transferase loci as a risk factor for common cancers. Arch. Toxicol.20(Suppl.),419–428 (1998).
  CASGoogle Scholar
• 64  Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res.54,4313–4320 (1994).
  Medline CASGoogle Scholar
• 65  Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR: Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis18,641–644 (1997).
  Medline CASGoogle Scholar
• 66  Kile ML, Houseman EA, Rodrigues E et al.: Toenail arsenic concentrations, GSTT1 gene polymorphisms, and arsenic exposure from drinking water. Cancer Epidemiol. Biomarkers Prev.14,2419–2426 (2005).
  Medline CASGoogle Scholar
• 67  Bernardini S, Nuccetelli M, Noguera NI et al.: Role of GSTP1-1 in mediating the effect of As₂O₃ in the acute promyelocytic leukemia cell line NB4. Ann. Hematol.85,681–687 (2006).
  Medline CASGoogle Scholar
• 68  McCarty KM, Chen YC, Quamruzzaman Q et al.: Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin lesions. Environ. Health Perspect.115,341–345 (2007).
  Medline CASGoogle Scholar
• 69  Breton CV, Kile ML, Catalano PJ et al.: GSTM1 and APE1 genotypes affect arsenic-induced oxidative stress: a repeated measures study. Environ. Health6,39 (2007).
  MedlineGoogle Scholar
• 70  Chiou HY, Hsueh YM, Hsieh LL et al.: Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat. Res.386,197–207 (1997).
  MedlineGoogle Scholar
• 71  Steinmaus C, Moore LE, Shipp M et al.: Genetic polymorphisms in MTHFR 677 and 1298, GSTM1 and T1, and metabolism of arsenic. J. Toxicol. Environ. Health A.70,159–170 (2007).
  Google Scholar
• 72  Marcos R, Martinez V, Hernandez A et al.: Metabolic profile in workers occupationally exposed to arsenic: role of GST polymorphisms. J. Occup. Environ. Med.48,334–341 (2006).
  Medline CASGoogle Scholar
• 73  Ghosh P, Basu A, Mahata J et al.: Cytogenetic damage and genetic variants in the individuals susceptible to arsenic-induced cancer through drinking water. Int. J. Cancer118,2470–2478 (2006).
  Medline CASGoogle Scholar
• 74  Lin GF, Du H, Chen JG et al.: Glutathione S-transferases M1 and T1 polymorphisms and arsenic content in hair and urine in two ethnic clans exposed to indoor combustion of high arsenic coal in southwest Guizhou, China. Arch. Toxicol.81,545–551 (2007).
  Medline CASGoogle Scholar
• 75  Adonis M, Martinez V, Marin P, Berrios D, Gil L: Smoking habit and genetic factors associated with lung cancer in a population highly exposed to arsenic. Toxicol. Lett.159,32–37 (2005).
  Medline CASGoogle Scholar
• 76  Hsu LI, Chiu AW, Huan SK et al.: SNPs of GSTM1,T1,P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Toxicol. Appl. Pharmacol.228,144–155 (2008).
  Medline CASGoogle Scholar
• 77  Wang YH, Wu MM, Hong CT et al.: Effects of arsenic exposure and genetic polymorphisms of p53, glutathione S-transferase M1, T1, and P1 on the risk of carotid atherosclerosis in Taiwan. Atherosclerosis192,305–312 (2007).
  Medline CASGoogle Scholar
• 78  McCarty KM, Ryan L, Houseman EA et al.: A case–control study of GST polymorphisms and arsenic related skin lesions. Environ. Health6,5 (2007).
  MedlineGoogle Scholar
• 79  Chen YC, Xu L, Guo YL et al.: Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: a preliminary study. Biomarkers9,386–394 (2004).
  Medline CASGoogle Scholar
• 80  Lin GF, Du H, Chen JG et al.: Arsenic-related skin lesions and glutathione S-transferase P1 A1578G (Ile105Val) polymorphism in two ethnic clans exposed to indoor combustion of high arsenic coal in one village. Pharmacogenet. Genomics16,863–871 (2006).
  Medline CASGoogle Scholar
• 81  Marafante E, Vahter M, Envall J: The role of the methylation in the detoxication of arsenate in the rabbit. Chem. Biol. Interact.56,225–238 (1985).
  Medline CASGoogle Scholar
• 82  Marafante E, Vahter M: The effect of methyltransferase inhibition on the metabolism of [74As]arsenite in mice and rabbits. Chem. Biol. Interact.50,49–57 (1984).
  Medline CASGoogle Scholar
• 83  Vahter M, Marafante E: Effects of low dietary intake of methionine, choline or proteins on the biotransformation of arsenite in the rabbit. Toxicol. Lett.37,41–46 (1987).
  Medline CASGoogle Scholar
• 84  Nelson GM, Ahlborn GJ, Delker DA et al.: Folate deficiency enhances arsenic effects on expression of genes involved in epidermal differentiation in transgenic K6/ODC mouse skin. Toxicology241,134–145 (2007).
  Medline CASGoogle Scholar
• 85  Frosst P, Blom HJ, Milos R et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet.10,111–113 (1995).
  Medline CASGoogle Scholar
• 86  Gamble MV, Ahsan H, Liu X et al.: Folate and cobalamin deficiencies and hyperhomocysteinemia in Bangladesh. Am. J. Clin. Nutr.81,1372–1377 (2005).
  Medline CASGoogle Scholar
• 87  Gamble MV, Liu X, Ahsan H et al.: Folate and arsenic metabolism: a double-blind, placebo-controlled folic acid-supplementation trial in Bangladesh. Am. J. Clin. Nutr.84,1093–1101 (2006).
  Medline CASGoogle Scholar
• 88  Gamble MV, Liu X, Ahsan H et al.: Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. Environ. Health Perspect.113,1683–1688 (2005).•• States the possible modulation of the nutritional status on the effects of arsenic. This cross-sectional study characterizes the relationships among folate, cobalamin, homocysteine and arsenic metabolism in Bangladeshi adults. Collectively, the reported data suggest that folate and other factors involved in one-carbon metabolism influence arsenic methylation.
  Medline CASGoogle Scholar
• 89  Gamble MV, Liu X, Slavkovich V et al.: Folic acid supplementation lowers blood arsenic. Am. J. Clin. Nutr.86,1202–1209 (2007).
  Medline CASGoogle Scholar
• 90  Gebel TW: Genotoxicity of arsenical compounds. Int. J. Hyg. Environ. Health.203,249–262 (2001).
  Medline CASGoogle Scholar
• 91  Bau DT, Wang TS, Chung CH, Wang AS, Wang AS, Jan KY: Oxidative DNA adducts and DNA-protein cross-links are the major DNA lesions induced by arsenite. Environ. Health Perspect.110(Suppl. 5),753–756 (2002).
  Medline CASGoogle Scholar
• 92  Hartwig A, Pelzer A, Asmuss M, Burkle A: Very low concentrations of arsenite suppress poly(ADP-ribosyl)ation in mammalian cells. Int. J. Cancer104,1–6 (2003).
  Medline CASGoogle Scholar
• 93  Poonepalli A, Balakrishnan L, Khaw AK et al.: Lack of poly(ADP-ribose) polymerase-1 gene product enhances cellular sensitivity to arsenite. Cancer Res.65,10977–10983 (2005).
  Medline CASGoogle Scholar
• 94  Schwerdtle T, Walter I, Hartwig A: Arsenite and its biomethylated metabolites interfere with the formation and repair of stable BPDE-induced DNA adducts in human cells and impair XPAzf and Fpg. DNA Repair (Amst.)2,1449–1463 (2003).
  Medline CASGoogle Scholar
• 95  Andrew AS, Karagas MR, Hamilton JW: Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int. J. Cancer104,263–268 (2003).• Interesting paper that is the only one that has studied the expression of critical members of the nucleotide-excision repair complex in human populations exposed to arsenic. Found that ERCC1, XPF and XPB expression was inversely correlated with the exposure measured by toenail arsenic levels.
  Medline CASGoogle Scholar
• 96  Breton CV, Zhou W, Kile ML et al.: Susceptibility to arsenic-induced skin lesions from polymorphisms in base excision repair genes. Carcinogenesis28,1520–1525 (2007).
  Medline CASGoogle Scholar
• 97  Banerjee M, Sarkar J, Das JK et al.: Polymorphism in the ERCC2 codon 751 is associated with arsenic-induced premalignant hyperkeratosis and significant chromosome aberrations. Carcinogenesis28,672–676 (2007).
  Medline CASGoogle Scholar
• 98  McCarty KM, Smith TJ, Zhou W et al.: Polymorphisms in XPD (Asp312Asn and Lys751Gln) genes, sunburn and arsenic-related skin lesions. Carcinogenesis28,1697–1702 (2007).
  Medline CASGoogle Scholar
• 99  Ahsan H, Chen Y, Wang Q, Slavkovich V, Graziano JH, Santella RM: DNA repair gene XPD and susceptibility to arsenic-induced hyperkeratosis. Toxicol. Lett.143,123–131 (2003).
  Medline CASGoogle Scholar
• 100  Applebaum KM, Karagas MR, Hunter DJ et al.: Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environ. Health Perspect.115,1231–1236 (2007).
  Medline CASGoogle Scholar
• 101  Spitz MR, Wu X, Wang Y et al.: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res.61,1354–1357 (2001).
  Medline CASGoogle Scholar
• 102  Mass MJ, Wang L: Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat. Res.386,263–277 (1997).
  Medline CASGoogle Scholar
• 103  Boonchai W, Walsh M, Cummings M, Chenevix-Trench G: Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch. Dermatol.136,195–198 (2000).
  Medline CASGoogle Scholar
• 104  Hsu CH, Yang SA, Wang JY, Yu HS, Lin SR: Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br. J. Cancer.80,1080–1086 (1999).
  Medline CASGoogle Scholar
• 105  de Chaudhuri S, Mahata J, Das JK et al.: Association of specific p53 polymorphisms with keratosis in individuals exposed to arsenic through drinking water in West Bengal, India. Mutat. Res.601,102–112 (2006).
  Medline CASGoogle Scholar
• 106  Chen YC, Guo YL, Su HJ et al.: Arsenic methylation and skin cancer risk in southwestern Taiwan. J. Occup. Environ. Med.45,241–248 (2003).
  Medline CASGoogle Scholar
• 107  Kessel M, Liu SX, Xu A, Santella R, Hei TK: Arsenic induces oxidative DNA damage in mammalian cells. Mol. Cell. Biochem.234–235(1–2),301–308 (2002).
  MedlineGoogle Scholar
• 108  Lee TC, Ho IC: Modulation of cellular antioxidant defense activities by sodium arsenite in human fibroblasts. Arch. Toxicol.69,498–504 (1995).
  Medline CASGoogle Scholar
• 109  Nandi D, Patra RC, Swarup D: Oxidative stress indices and plasma biochemical parameters during oral exposure to arsenic in rats. Food Chem. Toxicol.44,1579–1584 (2006).
  Medline CASGoogle Scholar
• 110  Mishra D, Mehta A, Flora SJ: Reversal of arsenic-induced hepatic apoptosis with combined administration of DMSA and its analogues in guinea pigs: role of glutathione and linked enzymes. Chem. Res. Toxicol.21,400–407 (2008).
  Medline CASGoogle Scholar
• 111  Xue DB, Zhang WH, Yun XG et al.: Regulating effects of arsenic trioxide on cell death pathways and inflammatory reactions of pancreatic acinar cells in rats. Chin. Med. J. (Engl.)120,690–695 (2007).
  Medline CASGoogle Scholar
• 112  Hsueh YM, Lin P, Chen HW et al.: Genetic polymorphisms of oxidative and antioxidant enzymes and arsenic-related hypertension. J. Toxicol. Environ. Health A.68,1471–1484 (2005).
  Medline CASGoogle Scholar
• 113  Ahsan H, Chen Y, Kibriya MG et al.: Susceptibility to arsenic-induced hyperkeratosis and oxidative stress genes myeloperoxidase and catalase. Cancer Lett.201,57–65 (2003).
  Medline CASGoogle Scholar
• 114  Falkner KC, McCallum GP, Cherian MG, Bend JR: Effects of acute sodium arsenite administration on the pulmonary chemical metabolizing enzymes, cytochrome P-450 monooxygenase, NAD(P)H:quinone acceptor oxidoreductase and glutathione S-transferase in guinea pig: comparison with effects in liver and kidney. Chem. Biol. Interact.86,51–68 (1993).
  Medline CASGoogle Scholar
• 115  Jacobs JM, Nichols CE, Andrew AS et al.: Effect of arsenite on induction of CYP1A, CYP2B, and CYP3A in primary cultures of rat hepatocytes. Toxicol. Appl. Pharmacol.157,51–59 (1999).
  Medline CASGoogle Scholar
• 116  Simeonova PP, Luster MI: Arsenic and atherosclerosis. Toxicol. Appl. Pharmacol.198,444–449 (2004).
  Medline CASGoogle Scholar
• 117  Hsieh YC, Hsieh FI, Lien LM, Chou YL, Chiou HY, Chen CJ: Risk of carotid atherosclerosis associated with genetic polymorphisms of apolipoprotein E and inflammatory genes among arsenic exposed residents in Taiwan. Toxicol. Appl. Pharmacol.227,1–7 (2008).
  Medline CASGoogle Scholar
• 118  Harrington JR: The role of MCP-1 in atherosclerosis. Stem Cells18,65–66 (2000).
  Medline CASGoogle Scholar
• 119  Simeonova PP, Hulderman T, Harki D, Luster MI: Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice. Environ. Health Perspect.111,1744–1748 (2003).
  Medline CASGoogle Scholar
• 120  Liu Z, Styblo M, Rosen BP: Methylarsonous acid transport by aquaglyceroporins. Environ. Health Perspect.114,527–531 (2006).•• Addresses how methylated arsenicals pass through cell membranes. Demonstrates that aquaglyceroporins differ both in selectivity for and transport rates of trivalent arsenicals into the cells. This study, together with others, leads us to suggest a new set of genes (polymorphisms) to be used in future association studies.
  Medline CASGoogle Scholar
• 121  Liu Z, Carbrey JM, Agre P, Rosen BP: Arsenic trioxide uptake by human and rat aquaglyceroporins. Biochem. Biophys. Res. Commun.316,1178–1185 (2004).
  Medline CASGoogle Scholar
• 122  Liu Z, Sanchez MA, Jiang X, Boles E, Landfear SM, Rosen BP: Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid. Biochem. Biophys. Res. Commun.351,424–430 (2006).
  Medline CASGoogle Scholar
• 123  Thomas DJ: Molecular processes in cellular arsenic metabolism. Toxicol. Appl. Pharmacol.222,365–373 (2007).•• Provides a basis for understanding the modes of action by which inorganic arsenic acts as a toxin and a carcinogen. Proposes the development of biologically based dose–response models describing the toxic and carcinogenic actions of arsenicals.
  Medline CASGoogle Scholar